Fate Therapeutics, Inc. (FATE)
Nasdaq · Healthcare · Biotechnology
$2.43+4.74%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $291M
- 52-week range
- $0.95 – $3.23
- 52-week change
- +64.54%
- EPS (trailing)
- −$1.05
- Analyst rating
- 2.2 Buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $6.6M (−51.24%)
- Net income
- −$136M
- Operating margin
- −2222.4%
- Diluted EPS
- −$1.15
- Free cash flow
- −$112M
From the company’s annual report on SEC EDGAR.
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 161 employees · fatetherapeutics.com